Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 5/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.51 |
| ▸ | RELA | Q04206 | 5/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4146153 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL28572940 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL2134157 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL13334908 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL12951314 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL31454795 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL605621 | 0.86 | NFKB1 (0.53) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL4951462 | 0.86 | NFKB1 (0.53) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL5270119 | 0.86 | NFKB1 (0.53) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL605148 | 0.86 | NFKB1 (0.53) | NFKB1NFKB2RELABTKCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102557990-B | Preparation method for (4-substituted amide)-2-cyclopentene-1-carboxylate raceme and single enantiomer thereof | KAIYUAN HENGTAI CHEMICAL CO LTD | 2014-06-25 | — | — | CN | claimed |
| CN-102372657-A | Synthesis method of anti-influenza and avian influenza virus resistant medicine peramivir | UNIV JINAN | 2012-03-14 | — | — | CN | claimed |
| EP-3892278-B1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2024-02-28 | — | — | EP | disclosed |
| CN-115504908-A | Preparation method of (1S, 4R) -4-tert-butoxycarbonylamino-cyclopent-2-alkenyl-1-methyl formate | 桂林南药股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-3892278-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020116662-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | 第一三共株式会社 | 2020-06-11 | — | — | WO | disclosed |
| EP-2834234-B1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-2834234-B1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-1763351-B9 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE HOLDINGS CORP (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-1763351-B1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE HOLDINGS CORP (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9150532-B2 | Fused cyclopentyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-06 | — | — | US | disclosed |
| US-7038059-B2 | Process for preparation of 4-n-substituted amino-2-aza-1-oxabicyclo[3.3.0] oct-2-ene-6-carboxylic acid esters and process for preparation of their intermediates | KURARAY CO., LTD. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20040121482-A1 | Process for preparation of 4-n-substituted amino-2-aza-1-oxabicyclo[3.3.0] oct-2-ene-6-carboxylic acid esters and process for preparation of their intermediates | KURARAY CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1334969-A1 | PROCESS FOR PREPARATION OF 4-N-SUBSTITUTED AMINO-2-AZA-1-OXABICYCLO 3.3.0]OCT-2-ENE-6-CARBOXYLIC ACID ESTERS AND PROCESS FOR PREPARATION OF THEIR INTERMEDIATES | KURARAY CO., LTD. (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-6503745-B1 | Method of detecting influenza virus, comprising the step of exposing a sample suspected to comprise influenza virus to at least one compound according to claim 1, wherein the at least one compound is capable of binding specifically to the active | BIOCRYST PHARMACEUTICALS, INC. | 2003-01-07 | — | — | US | disclosed |
| US-6495711-B2 | 1-(TERT-BUTOXYCARBONYLAMINO)-4-METHOXYCARBONYL-CYCLOPENT-2-ENE STARTING BY REACTING 2-AZABICYCLO(2.2.1)HEPT-5-EN-3-ONE WITH AN ALCOHOL AND NONAQUEOUS ACID; CHEMICAL INTERMEDIATES TO ANTIVIRAL AGENTS AGAINST INFLUENZA VIRUS | BIOCRYST PHARMACEUTICALS INC. | 2002-12-17 | — | — | US | disclosed |
| EP-1206443-A2 | PROCESS FOR PREPARING (-)-(1S,4R) N-PROTECTED 4-AMINO-2-CYCLOPENTENE-1-CARBOXYLATE ESTERS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2002-05-22 | — | — | EP | disclosed |
| US-20020052524-A1 | Process for preparing (-)-(1S, 4R) N-protected 4-amino-2-cyclopentene-1-carboxylate esters | BIOCRYST PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2001001569-A2 | PROCESS FOR PREPARING (-)-(1S,4R) N-PROTECTED 4-AMINO-2-CYCLOPENTENE-1-CARBOXYLATE ESTERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000028328-A1 | NEW CYCLOPENTANE AND CYCLOPENTENE COMPOUNDS AND USE FOR DETECTING INFLUENZA VIRUS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052524-A1 | Process for preparing (-)-(1S, 4R) N-protected 4-amino-2-cyclopentene-1-carboxylate esters | CPNE4, PYM1, CCNT1 | NFKB1 2824/4885NFKB2 3410/4885RELA 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.